Background-Early and accurate detection of HIV is crucial when using pre-exposure prophylaxis (PrEP) for HIV prevention to avoid PrEP initiation in acutely infected individuals and to minimize the risk of drug resistance in individuals with breakthrough infection.
Background
Early and accurate detection of HIV is crucial when using pre-exposure prophylaxis (PrEP) for HIV prevention to avoid PrEP initiation in acutely infected individuals and to minimize the risk of drug resistance in individuals with breakthrough infection [1] . The World Health Organization recommends two sequential rapid tests for HIV diagnosis [2] however third generation rapid tests detect only HIV antibodies and may miss up to 75% of early acute HIV infection cases [3] .
Fourth generation HIV rapid tests use a lateral flow cassette to separately assay for both anti-HIV antibodies and p24 antigen, however numerous studies have demonstrated the United States Food and Drug Administration (FDA)-approved Alere Determine™ HIV-1/2 Ag/Ab Combo to be insensitive for detection of acute infection. In a total of 54 acute seroconversion samples from 3 studies of acute infection from Malawi, Swaziland, Rwanda and Zambia, only 1 sample (1.9%) was positive for the p24 antigen component [4] [5] [6] . Reported sensitivity for antigen detection was higher in samples from the United Kingdom (50%), the United States (45.5% and 75.8%), Italy (88.2%) and in mixed-subtype seroconversion panels (86.6%) suggesting clade differences [3, [7] [8] [9] [10] . Evaluation of Gagexpressing virus-like particles (VLP) showed that 6 of 7 subtype B VLPs were detected by Alere Determine™ HIV-1/2 Ag/Ab Combo, compared to only 1 of 5 subtype C, and 3 of 31 non B/non-C-subtypes [11] .
In February 2015, Alere released a re-formulated fourth generation rapid test kit, the Conformité Européene (CE)-Marked Alere™ HIV Combo. Only one study to date has evaluated this new assay, reporting an 88% sensitivity compared to the Abbott Architect HIV Ag/Ab Combo assay using stored plasma or serum samples from the United Kingdom [12] . Also unknown is the performance of HIV confirmatory tests such as Bio-Rad Multispot ® HIV-1/HIV-2 Rapid Test, Geenius™ HIV-1/2 Supplemental Assay and GS HIV-1 Western Blot in the context of an algorithm that includes fourth generation rapids. This is the first evaluation of the new CE-Marked Alere™ HIV Combo in preseroconversion samples collected in South Africa, Uganda and Zimbabwe.
Objectives
The objective of this study was to evaluate the performance of third and fourth generation HIV rapid diagnostic tests and confirmatory assays to detect acute infection in a large cohort of participants from the MTN-003 (VOICE) HIV prevention trial.
Study design

Study population and specimen collection
VOICE (ClinicalTrials.gov NCT00705679) was a randomized, Phase 2 B placebo-controlled trial to evaluate the safety and effectiveness of oral tenofovir disoproxil fumarate (TDF), oral TDF-emtricitabine (FTC) and vaginal tenofovir 1% gel for the prevention of HIV infection in 5029 HIV-uninfected women from 15 clinical sites in South Africa, Uganda and Zimbabwe. Population characteristics and trial results have been described previously [13] .
In VOICE, participants were monitored monthly for seroconversion with one (Uganda) or two (South Africa and Zimbabwe) third generation HIV rapid diagnostic tests (RDT) performed point-of-care using venous or fingerstick-drawn whole blood at clinical research sites. RDTs used included Alere Determine™ HIV-1/2 (Alere Medical Co. Ltd., Matsudo, Japan), OraQuick ADVANCE ® Rapid HIV-1/2 Antibody Test (OraSure Technologies, Inc., Bethlehem, PA) and/or Uni-Gold™ Recombigen ® HIV-1/2 rapid test (Trinity Biotech™ Wicklow, Ireland). To diagnose HIV infection, clinical research sites followed an HIV algorithm during the study ( Fig. 1 ). Positive or discordant RDT results were confirmed by GS HIV-1 Western Blot (Bio-Rad Laboratories, Redmond, WA) using plasma from a separate draw and HIV-1 RNA PCR using Abbott RealTime HIV-1 (Abbott Molecular, Inc., Des Plaines, IL) was performed on plasma following an indeterminate or negative Western blot result to assess acute infection ( Fig. 1 ). Assay interpretation was defined by the manufacturer's package insert for each test. In the VOICE study, plasma from the visit at which seroconversion was detected and stored plasma from the seroconverting participant's enrollment visit were shipped to the University of Pittsburgh and re-tested to verify HIV infection using GS HIV-1/2 + O EIA (Bio-Rad), GS HIV-1 Western Blot and HIV-1 RNA PCR (Abbott).
Identification of specimens from acutely infected VOICE participants
After completion of the VOICE study, stored plasma specimens collected up to 91 days prior to detection of seroconversion were shipped to the University of Pittsburgh. Preseroconversion plasma specimens were tested for the presence of HIV-1 RNA by the COBAS ® AmpliPrep/COBAS ® TaqMan ® HIV-1 Test, v2.0 with a limit of quantitation of 20 copies/mL (Roche Diagnostics, Indianapolis, IN). Specimens with detectable HIV-1 RNA (including results of < 20 copies/mL, detected) were re-tested with OraQuick ADVANCE ® and Uni-Gold™ Recombigen ® and if antibody negative, were considered to be from an acutely infected participant. Only those specimens identified as "pre-seroconversion" defined as having detectable HIV-1 RNA and negative antibody reactivity were used for the evaluation of fourth generation RDTs.
Third and fourth generation diagnostic test evaluations
Third generation RDT-negative samples were tested with the fourth generation FDAapproved Alere™ Determine™ HIV-1/2 Ag/Ab Combo rapid test (Alere North America, Waltham, MA) and the CE-Marked Alere™ HIV Combo Rapid Test (Alere Medical Co. Ltd., Matsudo-chi, Japan) ( Supplementary Table S1 ). The Determine™ Combo and Alere™ HIV Combo RDTs are named similarly but have different formulations, different places of manufacture, and different performance specifications. Samples were also tested in duplicate by the third generation Bio-Rad GS HIV-1/2 + O Enzyme Immunoassay (EIA) and the fourth generation Bio-Rad GS HIV Combo Ag/Ab EIA, both FDA-Approved (Bio-Rad Laboratories).
Confirmatory test evaluations
Pre-seroconversion samples found to be positive by at least one of the above fourth generation tests were further tested for the presence of antibodies to HIV-1 and/or HIV-2 by Multispot ® HIV-1/HIV-2 Rapid Test, Geenius™ HIV-1/2 Supplemental Assay and GS HIV-1 Western Blot (Bio-Rad).
Statistical analysis
McNemar's test was used to compare the proportion of positive/reactive test results between assays. For calculating sensitivity, specificity, positive and negative predictive value of the results of the third generation HIV RDTs performed in VOICE, the gold standard was defined by the results of the study algorithm ( Fig. 1 ) which included additional WB and/or HIV-1 RNA testing by a local and/or central laboratory during the study. Samples that tested negative or indeterminate for RDT and/or WB but had detectable HIV-1 RNA were considered endpoints in the VOICE study. The gold standard for the same calculations on the results of the HIV tests evaluated in this study was detectable or undetectable HIV-1 RNA by Roche TaqMan. All confidence intervals are exact (Clopper-Pearson) 95% confidence intervals. 
Results
Third generation rapid test performance in VOICE
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Author Manuscript markedly lower than manufacturer's claims; Determine™ HIV-1/2 had the highest sensitivity at 88.78%, followed by Uni-Gold™ Recombigen ® at 85.86% and OraQuick ADVANCE ® at 61.54% (Table 1) .
Pre-Seroconversion HIV-1 RNA
The low sensitivity of third generation rapid tests for detecting seroconversion in VOICE was investigated using pre-seroconversion plasma. Of 312 participants who seroconverted in VOICE, stored plasma collected within 91 days prior to the date of the first positive pointof-care rapid test was available for 215 HIV-1 seroconverters from 246 visits. HIV-1 RNA was performed on 230 of 246 (93%) specimens (14 of 16 not tested had an undetectable HIV-1 RNA result at a closer visit; 2 of 16 had specimen integrity issues). Of 230 specimens, HIV-1 RNA was detected in 32 of 48 (67%) collected 12-29 days preseroconversion, 33 of 98 (34%) collected 30-59 days pre-seroconversion, and 7 of 84 (8%) collected 60-91 days pre-seroconversion ( Table 2 ).
4th generation rapid tests and immunoassays
Of 72 RNA-positive pre-seroconversion plasma specimens, 15 were positive for Uni-Gold ® Recombigen ® and/or OraQuick Advance ® upon re-testing and were excluded from further analysis ( 
Confirmatory tests
Because some HIV testing algorithms require confirmatory testing, we evaluated the concordance of fourth generation rapid test results with three Bio-Rad HIV confirmatory tests, Western blot, Multispot ® and Geenius™. Of 16 reactive CE-HIV Combo RDT samples, 9 were indeterminate by Western blot. Only one of 16 was reactive by Multispot ® , and no samples were reactive by Geenius™, with the exception of two specimens that were false reactive with a gp140 band yielding an HIV-2 indeterminate result (Table 3 ).
Discussion
Using pre-seroconversion plasma specimens from the VOICE study, we evaluated fourth generation RDT to determine if acute HIV infection would have been detected earlier compared to the third generation RDT used in the trial. The high incidence of acute infections in VOICE resulted in much lower sensitivities of third generation RDT (61.5% to 88.8%) relative to manufacturers' claims (99.6% to 100%) and confirmatory tests also performed poorly in detecting acute infection. In our study, 28% of infections from participants with detectable HIV-1 RNA and negative third generation RDT were detected by CE-HIV Combo. These data support the use of CE-HIV Combo in HIV diagnostic algorithms in high incidence settings.
Numerous studies have found the antigen component in fourth generation RDT to be insensitive and have reported that these tests do not provide any advantage for the diagnosis of acute infection [4] [5] [6] 9, 10, [14] [15] [16] [17] . Notably, we found major differences in test performance using two different versions of the same rapid test from the same company; CE-HIV Combo detected 21% more acute infections than FDA-Determine™ Combo. This is the first study to directly compare both versions of the Alere™ HIV Combo tests, and it highlights the importance of using the appropriate kit in diagnostic algorithms. The 4th Generation HIV Combo EIA had the highest improvement in detection of any test evaluated (47%) (Fig. 3) , however, cannot be used in algorithms requiring point-of-care testing.
Acute HIV detection is paramount for both PrEP clinical trials and PrEP rollout. In trials, delayed detection of infection can increase the number of person-years a participant is on an investigational product before reaching an endpoint, and more importantly, how long a participant continues taking an investigational product while already HIV infected. In five trials of TDF/FTC PrEP, the greatest risk of drug resistance occurred in participants who enrolled with undetected acute infection [1] . In VOICE, the majority of seroconverters obtained their HIV status within 3 months of acquiring HIV infection due to monthly testing, but the interval between infection and diagnosis in PrEP users outside the trial setting will be longer due to quarterly or less frequent HIV testing. Modeling studies are needed to evaluate the cost-benefit of implementing the CE-HIV Combo in PrEP programs.
Our study had several limitations. Plasma from seroconverters was stored quarterly, limiting the precision for calculating the exact number of days that the CE-HIV Combo could detect infection earlier than third generation RDT. We found that 15 of 230 specimens that tested negative by Uni-Gold™ Recombigen ® and/or OraQuick ADVANCE ® at clinical sites tested positive upon re-testing with stored plasma using the same RDT, suggesting that actual test sensitivity may be lower in point-of-care settings using fingerstick-collected blood compared to research settings due to imprecision in execution of test procedures.
The updated CE-Marked Alere™ HIV Combo Rapid Test has potential for improving current HIV algorithms for detection of acute HIV infection. Better confirmatory tests are needed to avoid discrepant results that require nucleic acid testing to resolve. Shortening the window period with antigen/antibody HIV tests will benefit individuals on PrEP for timely HIV diagnosis, and could help lower population-based incidence by decreasing transmission of HIV during acute infection. HIV Neg.
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